feed,title,long_url,short_url
MedRxiv,"The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV",https://medrxiv.org/cgi/content/short/2022.05.11.22274932v1?rss=1,https://bit.ly/3wnHsiq
